Peptides for Menopause: What Works and What Is Sold

Menopause is a growth market for peptide clinics, and the pitch is broad: sermorelin for the sleep and body-composition changes, NAD+ for the fatigue, GLP-1s for the weight that arrives with the transition, GHK-Cu for the skin. Almost none of it has been tested in menopausal women specifically.

Meanwhile the most important development in this field in a decade came directly out of peptide neuroscience — and the drug it produced is not a peptide. Fezolinetant blocks the neurokinin-3 receptor, part of the same hypothalamic neuron system kisspeptin belongs to, and it has Phase 3 evidence for moderate-to-severe vasomotor symptoms¹². That is the honest headline: the peptide science was real and productive, and what it produced is a small molecule you get from a doctor rather than an injectable you get from a clinic.

This page separates the two, and covers what is genuinely worth knowing about the compounds women are being sold.

The Hot-Flash Story — Real Science, Non-Peptide Answer

Vasomotor symptoms — hot flashes and night sweats — are the defining symptom of the menopause transition for most women who seek treatment³.

The mechanism turned out to run through a group of hypothalamic neurons known as KNDy, for the three signals they co-express: kisspeptin, neurokinin B and dynorphin. This is the same kisspeptin that appears in peptides for testosterone — the neuron cluster does double duty in reproductive signaling and thermoregulation. When estrogen falls, signaling through this system changes, and that change drives the flush.

Blocking the neurokinin-3 receptor interrupts it. Fezolinetant does exactly that, and the Phase 3 evidence covers onset, maintenance of effect and day- versus night-time symptoms¹, with systematic review and meta-analysis of the randomized trials² and profiles of its efficacy and safety⁴. A dual neurokinin-1/-3 antagonist, elinzanetant, has followed with its own safety literature⁵.

Note what this is and is not. It is a genuine, rigorous, non-hormonal option for the symptom women most want treated. It is a prescription small molecule, evaluated by a regulator, with published liver-safety monitoring requirements. It is not something sold on a peptide menu, and no injectable peptide has anything comparable for this symptom.

That same neuron system is where the mechanistic confirmation cuts both ways: neurokinin-3 antagonism decreases gonadotropin and testosterone secretion in men⁶, which is the same pathway being modulated for a different purpose.

What Is Actually Sold to Women in Perimenopause

Now the peptide menu, taken honestly, item by item.

GH peptides — sermorelin, ipamorelin, CJC-1295. Sold for sleep, energy and body composition, all of which genuinely change in the transition. The pooled human evidence on the growth-hormone axis found increased lean body mass that reviewers attributed largely to fluid retention, with no improvement in strength or exercise capacity and more adverse events⁷. Worse for this audience specifically: the closest controlled test of that axis and sleep found that systemic GHRH impaired sleep in healthy young women⁸ — a result generated in women, pointing the wrong way, that no product page mentions. We cover it in peptides for sleep.

NAD+ and the mitochondrial compounds. Sold for the fatigue. The human trial record is not encouraging and we set it out in peptides for energy and NAD+ injections.

GHK-Cu and skin peptides. The topical evidence is real and dermatological; the injectable systemic claims are not — see GHK-Cu. For the hair question specifically, which arrives for many women in this transition, see peptides for hair growth.

GLP-1s. These are the exception: they have randomized evidence, they work, and they are peptides. But there are two things to know that matter more in this population than in any other, and both are covered below.

The Two GLP-1 Considerations That Matter Most Here

Lean tissue. A substantial share of the weight lost on a GLP-1 is lean mass rather than fat, and the proportion differs between molecules. The menopause transition already carries an unfavorable shift in body composition, and losing muscle on top of that is a real cost rather than a footnote. It is the single most under-discussed fact in this category and we cover it in semaglutide, tirzepatide and muscle loss. The practical implication is resistance training and adequate protein alongside, not instead of, whatever else is decided.

Perimenopause is not menopause. Pregnancy remains possible during the transition, and that matters because the labeled instructions differ by molecule — the contraceptive instruction attaches to tirzepatide and not to semaglutide. Anyone still cycling, however irregularly, is making a decision the labeling treats as live. This is the ranking criterion on best weight loss peptides for women, where a provider that will not tell you which molecule you are receiving ranks last regardless of price. The underlying trial evidence for semaglutide's weight-loss use is the STEP program⁹.

For the wider evidence review in women, including which peptides have any human data at all in this population, see peptides for women: the evidence.

The Symptom List Nobody Sells Against

Vasomotor symptoms get the drug development because they are measurable and miserable. The rest of the transition is where the peptide clinics actually recruit, and it is worth separating what is genuinely happening from what is being attributed.

Sleep disruption is real and often the most damaging symptom. It is also frequently downstream of night sweats, which means treating the flush can treat the sleep — and the GH peptides sold for it have a controlled human result pointing the wrong way in women⁸.

Body composition genuinely shifts across the transition, and this is where the GLP-1 lean-tissue question below becomes more than academic.

Cognitive complaints — the "brain fog" of perimenopause — are commonly reported and poorly served. Nothing on a peptide menu has controlled evidence in this population; the cognitive peptides are covered in nootropic peptides, where the published human work sits in patients with dementia rather than healthy adults.

Mood and anxiety changes are likewise real and likewise unserved by this market — see peptides for anxiety, where the best available evidence is one small study without a placebo arm.

The honest summary: a clinic selling a peptide stack for the transition is selling against a symptom list where one item has a properly evidenced non-peptide option, one has a GH result pointing the wrong way, and the rest have nothing tested in menopausal women at all.

What This Costs

The compounds sold for the transition are priced as ongoing subscriptions, and advertised rates in this market frequently describe a term rather than a price.

Hone Health's sermorelin page shows "$130/mo" against a real figure of $285, because the product sits on a tier requiring a $155 membership — and fourteen states plus D.C. cannot buy it at all. Live Vital advertises NAD+ at "$83/mo" against a ten-week protocol totaling $249, which is nearer $108 a month. Rylo Health advertises sermorelin at "$183/mo", which is $549 every three months; paid monthly it is $249.

On the GLP-1 side, SkinnyRx advertises "As low as $199/mo" when the rate you can stop paying after one month is $349, and Care Bare Rx names four GLP-1 products while publishing a price for none of them. HealthRX publishes the whole ladder with prepay marked optional, which is what the fair version looks like.

Boards: best semaglutide providers, best NAD+ injection providers, best sermorelin providers, all indexed on the rankings index with figures in the price transparency index.

Bottom Line

The peptide science around menopause is genuinely good, and it did not produce a peptide product.

Understanding the KNDy neuron system — kisspeptin, neurokinin B, dynorphin — is what made non-hormonal treatment of hot flashes possible, and the resulting neurokinin-3 antagonists have Phase 3 evidence for the symptom women most want treated¹²⁴. They are prescription small molecules with monitoring requirements, not injectables from a peptide menu.

What is sold on peptide menus for this transition mostly has not been tested in this population, and one part of it has a controlled result pointing the wrong way — systemic GHRH impaired sleep in women⁸, while the GH axis overall showed lean-mass gain that was largely fluid with no strength benefit⁷.

GLP-1s are the real exception, with randomized evidence behind them⁹ — carrying two caveats that land harder here than anywhere else: the lean-tissue cost against a transition that already shifts body composition, and the labeled contraceptive difference between molecules for anyone still cycling.

For how each compound grades against human evidence, see what are peptides good for and the research library.